

Public Health Key Documents: September 2021

NIHR

A prognostic model, including quantitative fetal fibronectin, to predict preterm labour: the QUIDS meta-analysis and prospective cohort study

This study developed a prognostic model, including quantitative fetal fibronectin and clinical risk factors, that showed excellent performance in predicting spontaneous preterm birth within 7 days.

Systematic search: Yes

September 2021

<https://www.journalslibrary.nihr.ac.uk/hta/hta25520/#/abstract>

Medications for chronic obstructive pulmonary disease: a historical non-interventional cohort study with validation against RCT results

This study demonstrated the utility of non-interventional data to investigate the expected treatment effects of COPD medications and analyses largely suggest COPD treatment effects are consistent across different patient groups.

Systematic search: No

August 2021

<https://www.journalslibrary.nihr.ac.uk/hta/hta25510/#/abstract>

The King's Fund

Anchor institutions and how they can affect people's health

Anchor institutions are large organisations that are unlikely to relocate and have a significant stake in their local area. They have sizeable assets that can be used to support their local community's health and wellbeing and tackle health inequalities, for example, through procurement, training, employment, buildings and land use. NHS organisations and local authorities (as anchor organisations) can play a role in addressing the socio-economic factors that lead to health inequalities.

Systematic search: No

September 2021

<https://www.kingsfund.org.uk/publications/anchor-institutions-and-peoples-health>

Scottish Medicines Consortium (SMC Advice)

pembrolizumab (Keytruda®)

Accepted for restricted use as monotherapy for the first-line treatment of metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in adults. Treatment is subject to a two-year clinical stopping rule.

Systematic search: No

September 2021

<https://www.scottishmedicines.org.uk/medicines-advice/pembrolizumab-keytruda-cc-full-smc2375/>

filgotinib (Jyseleca®)

Accepted for restricted use for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Filgotinib may be used as monotherapy or in combination with methotrexate (MTX). Restricted to patients with severe disease (a disease activity score [DAS28] greater than 5.1) that has not responded to intensive therapy with a combination of

conventional DMARDs and in patients with severe disease inadequately controlled by a TNF antagonist in whom rituximab is not appropriate.

Systematic search: No

September 2021

<https://www.scottishmedicines.org.uk/medicines-advice/filgotinib-jyseleca-full-smc2365/>

amikacin liposomal nebuliser dispersion (Arikayce®)

NOT recommended for the treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) in adults with limited treatment options who do not have cystic fibrosis. Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Systematic search: No

September 2021

<https://www.scottishmedicines.org.uk/medicines-advice/amikacin-arikayce-full-smc2369/>

selpercatinib (Retsevmo®)

Accepted for use on an interim basis subject to ongoing evaluation and future reassessment. Selpercatinib as monotherapy is indicated for the treatment of adults with advanced RET fusion-positive thyroid cancer who require systemic therapy following prior treatment with sorafenib and/or lenvatinib. Selpercatinib as monotherapy is also indicated for the treatment of adults and adolescents 12 years and older with advanced RET-mutant medullary thyroid cancer (MTC) who require systemic therapy following prior treatment with cabozantinib and/or vandetanib.

Systematic search: No

September 2021

<https://www.scottishmedicines.org.uk/medicines-advice/selpercatinib-retsevmo-tc-full-smc2370/>

mercaptamine (Procysbi®)

NOT recommended for use for the treatment of proven nephropathic cystinosis.

Systematic search: No

September 2021

<https://www.scottishmedicines.org.uk/medicines-advice/mercaptamine-procysbi-resub-smc2374/>

Scottish Government

The Best Start - caesarean section rates: review report

Report covers the rising caesarean section rate in Scotland and explores the factors contributing to this by exploring published data and evidence within Scotland, across the UK and wider where applicable.

Systematic search: No

September 2021

<https://www.gov.scot/publications/best-start-review-caesarean-section-rates-scotland/>

Please note: Covid-19 data and statistics, advice and guidance are available from <https://www.gov.scot/coronavirus-covid-19/> with further publications available at <https://www.gov.scot/publications/?topics=Coronavirus+in+Scotland>

SIGN

A DRAFT **rapid national clinical guideline on the prevention and management of venous thromboembolism in patients with COVID-19** has been released for comment by 3rd October – see <https://www.sign.ac.uk/media/1893/20210915-prevention-and-management-of-thromboembolism-peer-review-draft.pdf> Comments can be made at <https://www.smartsurvey.co.uk/s/EQVTTI/>

An **update** to the **guideline on Managing the long-term effects of COVID-19** in collaboration with NICE and RCGP is in progress and due in **Autumn 2021**.

Public Health Scotland

Prioritise child poverty: a data and systems approach

Documents from a joint Public Health Scotland and Inverclyde Council project describing a public health needs assessment approach to understand the local child poverty system and shape local child poverty priorities.

Systematic search: No

September 2021

<https://www.publichealthscotland.scot/publications/prioritise-child-poverty-a-data-and-systems-approach>

An animation showing the approach taken can be viewed at <https://vimeo.com/586307092>

NICE – Guidelines

Nil since August 2021 Key Documents list.

NICE - Technology Appraisal Guidance

TA728 Midostaurin for treating advanced systemic mastocytosis

Systematic search: Yes

September 2021

<https://www.nice.org.uk/guidance/ta728>

TA729 Sapropterin for treating hyperphenylalaninaemia in phenylketonuria

Systematic search: Yes

September 2021

<https://www.nice.org.uk/guidance/ta729>

TA725 Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy

Systematic search: Yes

September 2021

<https://www.nice.org.uk/guidance/ta725>

TA724 Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer

Systematic search: Yes

September 2021

<https://www.nice.org.uk/guidance/ta724>

TA723 Bimekizumab for treating moderate to severe plaque psoriasis

Systematic search: Yes

September 2021

<https://www.nice.org.uk/guidance/ta723>

EPPI Centre

Mitigating impacts of the COVID-19 pandemic on primary and lower secondary children during school closures (rapid review)

Systematic search: Limited

September 2021

<https://eppi.ioe.ac.uk/cms/Default.aspx?tabid=3837>

Mitigating impacts of the COVID-19 pandemic on the further education sector (rapid review)

Systematic search: Limited

September 2021

<https://eppi.ioe.ac.uk/cms/Default.aspx?tabid=3838>

Mitigating impacts of the COVID-19 pandemic on higher education (rapid review)

Systematic search: Limited

September 2021

<https://eppi.ioe.ac.uk/cms/Default.aspx?tabid=3839>

Mitigating impacts of the COVID-19 pandemic on parents and carers during school closures (rapid review)

Systematic search: Limited

September 2021

<https://eppi.ioe.ac.uk/cms/Default.aspx?tabid=3840>

AHRQ (Agency for Healthcare Research and Quality – USA)

Interventional Treatments for Acute and Chronic Pain: Systematic Review

Vertebroplasty is probably effective at reducing pain and improving function in older patients with vertebral compression fractures; benefits are small but similar to other therapies recommended for pain. Evidence was too limited to separate effects of control type and symptom acuity on effectiveness of vertebroplasty. Kyphoplasty has not been compared against sham but is probably more effective than usual care for vertebral compression fractures in older patients. In younger populations, cooled radiofrequency denervation is probably more effective than sham for sacroiliac pain. Research is needed to determine the benefits and harms of the other interventional procedures and conditions addressed in this review.

Systematic search: Yes

September 2021

<https://effectivehealthcare.ahrq.gov/products/interventional-treatments-pain/research>

Health Foundation

The NHS Long Term Plan and COVID-19: Assessing progress and the pandemic's impact

In 2019, the NHS Long Term Plan set out a 10-year strategy for improving and reforming the NHS in England. Some long term plan commitments have been accelerated by the COVID-19 response, such

as improving access to remote consultations in primary care and outpatients. However, the overall picture is of one of major delay, disruption and increased demands on services. Previous national targets – such as for expanding access to mental health services – will need to be revised to account for greater need.

Systematic search: No

September 2021

<https://www.health.org.uk/publications/reports/the-nhs-long-term-plan-and-covid-19>

Waiting for care: Understanding the pandemic's effects on people's health and quality of life

The suspension of routine NHS care has affected people's health and wellbeing – with the significance of this depending on the type of condition or treatment delayed. This analysis explores the implications of this via two case studies – hip replacements and diabetes.

Systematic search: No

August 2021

<https://www.health.org.uk/publications/long-reads/waiting-for-care>

Canadian Agency for drugs and Technologies in Health (CADTH)

Hip Protectors for Community-Dwelling Older Adults

In community-dwelling older adults who wore hip protectors there was no difference in the risk of hip fractures or pelvic fractures, compared to those who did not wear hip protectors.

Systematic search: Limited

September 2021

<https://www.cadth.ca/hip-protectors-community-dwelling-older-adults>

McGill University Health Centre (Canada)

Nil

Health Information & Quality Authority (Ireland) – Health Technology Assessments

Nil

Campbell Collaboration

Nil

Glasgow Centre for Population Health

Nil

NICE FORWARD PLANNING – Publications due October 2021

DyeVert Systems for reducing the risk of acute kidney injury in coronary and peripheral angiography

Medical Technology

Prontosan for acute and chronic wounds

Medical Technology

Nivolumab in combination with chemotherapy for untreated advanced gastric or gastro-oesophageal junction cancer

Single Technology Appraisal

Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma

Single Technology Appraisal

Pembrolizumab with platinum-based chemotherapy for untreated advanced oesophageal cancer

Single Technology Appraisal

Berotrastat for preventing recurrent attacks of hereditary angioedema

Single Technology Appraisal

Looked-after children and young people

Public health guideline

Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer

Single Technology Appraisal

Cabotegravir and rilpivirine for treating HIV-1

Single Technology Appraisal

Tofacitinib for treating juvenile idiopathic arthritis

Single Technology Appraisal

Secukinumab for treating plaque psoriasis in children and young people

Single Technology Appraisal

Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable

Single Technology Appraisal

Heart valve disease presenting in adults: investigation and management

Clinical Guideline

Apalutamide for treating prostate cancer

Single Technology Appraisal